Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/art.41469 http://scihub22266oqcxt.onion/10.1002/art.41469 32741139!7435536!32741139     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Arthritis+Rheumatol 2021 ; 73 (1): 36-47 Nephropedia Template TP {{tp|p=32741139|t=2021. Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis |pdf=|usr=}}{{32741139}} gab.com Text Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis JO: Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=32741139 #FOAvip OBJECTIVE: Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. We conducted a systematic review and meta-analysis to describe the current evidence. METHODS: A search of published and preprint databases in all languages was performed. Included studies described >/=1 relevant clinical outcome for >/=5 patients who were infected with severe acute respiratory syndrome coronavirus 2 and were treated with antirheumatic disease therapy between January 1, 2019 and May 29, 2020. Pairs of reviewers screened articles, extracted data, and assessed risk of bias. A meta-analysis of effect sizes using random-effects models was performed when possible. RESULTS: The search identified 3,935 articles, of which 45 were included (4 randomized controlled trials, 29 cohort studies, and 12 case series). All studies evaluated hospitalized patients, and 29 of the 45 studies had been published in a peer-reviewed journal. In a meta-analysis of 3 cohort studies with a low risk of bias, hydroxychloroquine use was not significantly associated with mortality (pooled hazard ratio [HR] 1.41 [95% confidence interval (95% CI) 0.83, 2.42]). In a meta-analysis of 2 cohort studies with some concerns/higher risk of bias, anakinra use was associated with lower mortality (pooled HR 0.25 [95% CI 0.12, 0.52]). Evidence was inconclusive with regard to other antirheumatic disease therapies, and the majority of other studies had a high risk of bias. CONCLUSION: In this systematic review and meta-analysis, hydroxychloroquine use was not associated with benefit or harm regarding COVID-19 mortality. The evidence supporting the effect of other antirheumatic disease therapies in COVID-19 is currently inconclusive. Twit Text FOAVip Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis ????Arthritis Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=32741139 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32741139 #FOAvip English Wikipedia <ref>{{Cite pmid|32741139}}</ref> Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis #MMPMID32741139 Putman M; Chock YPE; Tam H; Kim AHJ; Sattui SE; Berenbaum F; Danila MI; Korsten P; Sanchez-Alvarez C; Sparks JA; Coates LC; Palmerlee C; Peirce A; Jayatilleke A; Johnson SR; Kilian A; Liew J; Prokop LJ; Murad MH; Grainger R; Wallace ZS; Duarte-Garcia A Arthritis Rheumatol 2021[Jan]; 73 (1): 36-47 PMID32741139show ga OBJECTIVE: Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. We conducted a systematic review and meta-analysis to describe the current evidence. METHODS: A search of published and preprint databases in all languages was performed. Included studies described >/=1 relevant clinical outcome for >/=5 patients who were infected with severe acute respiratory syndrome coronavirus 2 and were treated with antirheumatic disease therapy between January 1, 2019 and May 29, 2020. Pairs of reviewers screened articles, extracted data, and assessed risk of bias. A meta-analysis of effect sizes using random-effects models was performed when possible. RESULTS: The search identified 3,935 articles, of which 45 were included (4 randomized controlled trials, 29 cohort studies, and 12 case series). All studies evaluated hospitalized patients, and 29 of the 45 studies had been published in a peer-reviewed journal. In a meta-analysis of 3 cohort studies with a low risk of bias, hydroxychloroquine use was not significantly associated with mortality (pooled hazard ratio [HR] 1.41 [95% confidence interval (95% CI) 0.83, 2.42]). In a meta-analysis of 2 cohort studies with some concerns/higher risk of bias, anakinra use was associated with lower mortality (pooled HR 0.25 [95% CI 0.12, 0.52]). Evidence was inconclusive with regard to other antirheumatic disease therapies, and the majority of other studies had a high risk of bias. CONCLUSION: In this systematic review and meta-analysis, hydroxychloroquine use was not associated with benefit or harm regarding COVID-19 mortality. The evidence supporting the effect of other antirheumatic disease therapies in COVID-19 is currently inconclusive. |*COVID-19 Drug Treatment[MESH] |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |Antibodies, Monoclonal/therapeutic use[MESH] |Antirheumatic Agents/*therapeutic use[MESH] |Azetidines/therapeutic use[MESH] |Bias[MESH] |COVID-19/mortality/physiopathology[MESH] |Chloroquine/therapeutic use[MESH] |Disease Progression[MESH] |Glucocorticoids/therapeutic use[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Immunoglobulins, Intravenous/therapeutic use[MESH] |Immunologic Factors/therapeutic use[MESH] |Interleukin 1 Receptor Antagonist Protein/therapeutic use[MESH] |Janus Kinase Inhibitors/therapeutic use[MESH] |Proportional Hazards Models[MESH] |Purines/therapeutic use[MESH] |Pyrazoles/therapeutic use[MESH] |SARS-CoV-2[MESH]Antirheumatic Disease Therapies for the Treatment of COVID-19: A Syste(epmc).pdf DeepDyve Pubget Overpricing